Emergency care of patients receiving non-vitamin K antagonist oral anticoagulants

J. W. Eikelboom, S. Kozek-Langenecker, A. Exadaktylos, A. Batorova, Z. Boda, F. Christory, I. Gornik, G. Kėkštas, A. Kher, R. Komadina, O. Koval, G. Mitic, T. Novikova, E. Pazvanska, S. Ratobilska, J. Sütt, A. Winder, D. Zateyshchikov

Research output: Contribution to journalReview article

3 Citations (Scopus)

Abstract

Non-vitamin K antagonist oral anticoagulants (NOACs), which inhibit thrombin (dabigatran) and factor Xa (rivaroxaban, apixaban, edoxaban) have been introduced in several clinical indications. Although NOACs have a favourable benefit-risk profile and can be used without routine laboratory monitoring, they are associated–as any anticoagulant–with a risk of bleeding. In addition, treatment may need to be interrupted in patients who need surgery or other procedures. The objective of this article, developed by a multidisciplinary panel of experts in thrombosis and haemostasis, is to provide an update on the management of NOAC-treated patients who experience a bleeding episode or require an urgent procedure. Recent advances in the development of targeted reversal agents are expected to help streamline the management of NOAC-treated patients in whom rapid reversal of anticoagulation is required.

Original languageEnglish
Pages (from-to)645-656
Number of pages12
JournalBritish Journal of Anaesthesia
Volume120
Issue number4
DOIs
Publication statusPublished - Apr 1 2018

Fingerprint

Emergency Medical Services
Anticoagulants
Hemorrhage
Factor Xa
Hemostasis
Thrombin
Thrombosis
Therapeutics

Keywords

  • anticoagulants
  • coagulation monitoring
  • emergencies
  • haemorrhage
  • reversal

ASJC Scopus subject areas

  • Anesthesiology and Pain Medicine

Cite this

Eikelboom, J. W., Kozek-Langenecker, S., Exadaktylos, A., Batorova, A., Boda, Z., Christory, F., ... Zateyshchikov, D. (2018). Emergency care of patients receiving non-vitamin K antagonist oral anticoagulants. British Journal of Anaesthesia, 120(4), 645-656. https://doi.org/10.1016/j.bja.2017.11.082

Emergency care of patients receiving non-vitamin K antagonist oral anticoagulants. / Eikelboom, J. W.; Kozek-Langenecker, S.; Exadaktylos, A.; Batorova, A.; Boda, Z.; Christory, F.; Gornik, I.; Kėkštas, G.; Kher, A.; Komadina, R.; Koval, O.; Mitic, G.; Novikova, T.; Pazvanska, E.; Ratobilska, S.; Sütt, J.; Winder, A.; Zateyshchikov, D.

In: British Journal of Anaesthesia, Vol. 120, No. 4, 01.04.2018, p. 645-656.

Research output: Contribution to journalReview article

Eikelboom, JW, Kozek-Langenecker, S, Exadaktylos, A, Batorova, A, Boda, Z, Christory, F, Gornik, I, Kėkštas, G, Kher, A, Komadina, R, Koval, O, Mitic, G, Novikova, T, Pazvanska, E, Ratobilska, S, Sütt, J, Winder, A & Zateyshchikov, D 2018, 'Emergency care of patients receiving non-vitamin K antagonist oral anticoagulants', British Journal of Anaesthesia, vol. 120, no. 4, pp. 645-656. https://doi.org/10.1016/j.bja.2017.11.082
Eikelboom JW, Kozek-Langenecker S, Exadaktylos A, Batorova A, Boda Z, Christory F et al. Emergency care of patients receiving non-vitamin K antagonist oral anticoagulants. British Journal of Anaesthesia. 2018 Apr 1;120(4):645-656. https://doi.org/10.1016/j.bja.2017.11.082
Eikelboom, J. W. ; Kozek-Langenecker, S. ; Exadaktylos, A. ; Batorova, A. ; Boda, Z. ; Christory, F. ; Gornik, I. ; Kėkštas, G. ; Kher, A. ; Komadina, R. ; Koval, O. ; Mitic, G. ; Novikova, T. ; Pazvanska, E. ; Ratobilska, S. ; Sütt, J. ; Winder, A. ; Zateyshchikov, D. / Emergency care of patients receiving non-vitamin K antagonist oral anticoagulants. In: British Journal of Anaesthesia. 2018 ; Vol. 120, No. 4. pp. 645-656.
@article{49be0ccf1829447a875bbdc8cdbc084c,
title = "Emergency care of patients receiving non-vitamin K antagonist oral anticoagulants",
abstract = "Non-vitamin K antagonist oral anticoagulants (NOACs), which inhibit thrombin (dabigatran) and factor Xa (rivaroxaban, apixaban, edoxaban) have been introduced in several clinical indications. Although NOACs have a favourable benefit-risk profile and can be used without routine laboratory monitoring, they are associated–as any anticoagulant–with a risk of bleeding. In addition, treatment may need to be interrupted in patients who need surgery or other procedures. The objective of this article, developed by a multidisciplinary panel of experts in thrombosis and haemostasis, is to provide an update on the management of NOAC-treated patients who experience a bleeding episode or require an urgent procedure. Recent advances in the development of targeted reversal agents are expected to help streamline the management of NOAC-treated patients in whom rapid reversal of anticoagulation is required.",
keywords = "anticoagulants, coagulation monitoring, emergencies, haemorrhage, reversal",
author = "Eikelboom, {J. W.} and S. Kozek-Langenecker and A. Exadaktylos and A. Batorova and Z. Boda and F. Christory and I. Gornik and G. Kėkštas and A. Kher and R. Komadina and O. Koval and G. Mitic and T. Novikova and E. Pazvanska and S. Ratobilska and J. S{\"u}tt and A. Winder and D. Zateyshchikov",
year = "2018",
month = "4",
day = "1",
doi = "10.1016/j.bja.2017.11.082",
language = "English",
volume = "120",
pages = "645--656",
journal = "British Journal of Anaesthesia",
issn = "0007-0912",
publisher = "Oxford University Press",
number = "4",

}

TY - JOUR

T1 - Emergency care of patients receiving non-vitamin K antagonist oral anticoagulants

AU - Eikelboom, J. W.

AU - Kozek-Langenecker, S.

AU - Exadaktylos, A.

AU - Batorova, A.

AU - Boda, Z.

AU - Christory, F.

AU - Gornik, I.

AU - Kėkštas, G.

AU - Kher, A.

AU - Komadina, R.

AU - Koval, O.

AU - Mitic, G.

AU - Novikova, T.

AU - Pazvanska, E.

AU - Ratobilska, S.

AU - Sütt, J.

AU - Winder, A.

AU - Zateyshchikov, D.

PY - 2018/4/1

Y1 - 2018/4/1

N2 - Non-vitamin K antagonist oral anticoagulants (NOACs), which inhibit thrombin (dabigatran) and factor Xa (rivaroxaban, apixaban, edoxaban) have been introduced in several clinical indications. Although NOACs have a favourable benefit-risk profile and can be used without routine laboratory monitoring, they are associated–as any anticoagulant–with a risk of bleeding. In addition, treatment may need to be interrupted in patients who need surgery or other procedures. The objective of this article, developed by a multidisciplinary panel of experts in thrombosis and haemostasis, is to provide an update on the management of NOAC-treated patients who experience a bleeding episode or require an urgent procedure. Recent advances in the development of targeted reversal agents are expected to help streamline the management of NOAC-treated patients in whom rapid reversal of anticoagulation is required.

AB - Non-vitamin K antagonist oral anticoagulants (NOACs), which inhibit thrombin (dabigatran) and factor Xa (rivaroxaban, apixaban, edoxaban) have been introduced in several clinical indications. Although NOACs have a favourable benefit-risk profile and can be used without routine laboratory monitoring, they are associated–as any anticoagulant–with a risk of bleeding. In addition, treatment may need to be interrupted in patients who need surgery or other procedures. The objective of this article, developed by a multidisciplinary panel of experts in thrombosis and haemostasis, is to provide an update on the management of NOAC-treated patients who experience a bleeding episode or require an urgent procedure. Recent advances in the development of targeted reversal agents are expected to help streamline the management of NOAC-treated patients in whom rapid reversal of anticoagulation is required.

KW - anticoagulants

KW - coagulation monitoring

KW - emergencies

KW - haemorrhage

KW - reversal

UR - http://www.scopus.com/inward/record.url?scp=85045918679&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85045918679&partnerID=8YFLogxK

U2 - 10.1016/j.bja.2017.11.082

DO - 10.1016/j.bja.2017.11.082

M3 - Review article

VL - 120

SP - 645

EP - 656

JO - British Journal of Anaesthesia

JF - British Journal of Anaesthesia

SN - 0007-0912

IS - 4

ER -